TW200848042A - Quinoline-carboxamide derivatives as P2Y12 antagonists - Google Patents
Quinoline-carboxamide derivatives as P2Y12 antagonists Download PDFInfo
- Publication number
- TW200848042A TW200848042A TW097114392A TW97114392A TW200848042A TW 200848042 A TW200848042 A TW 200848042A TW 097114392 A TW097114392 A TW 097114392A TW 97114392 A TW97114392 A TW 97114392A TW 200848042 A TW200848042 A TW 200848042A
- Authority
- TW
- Taiwan
- Prior art keywords
- alkylene
- oxo
- ethoxy
- carbonyl
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrrole Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07008209 | 2007-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200848042A true TW200848042A (en) | 2008-12-16 |
Family
ID=38462433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW097114392A TW200848042A (en) | 2007-04-23 | 2008-04-21 | Quinoline-carboxamide derivatives as P2Y12 antagonists |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8669266B2 (enExample) |
| EP (1) | EP2148871A1 (enExample) |
| JP (1) | JP5309131B2 (enExample) |
| KR (1) | KR20100015886A (enExample) |
| CN (1) | CN101663293B (enExample) |
| AR (1) | AR066225A1 (enExample) |
| AU (1) | AU2008241091B2 (enExample) |
| BR (1) | BRPI0810462A2 (enExample) |
| CA (1) | CA2684644A1 (enExample) |
| CL (1) | CL2008001157A1 (enExample) |
| IL (1) | IL201620A (enExample) |
| MX (1) | MX2009011089A (enExample) |
| MY (1) | MY153427A (enExample) |
| PA (1) | PA8777901A1 (enExample) |
| PE (1) | PE20090241A1 (enExample) |
| TW (1) | TW200848042A (enExample) |
| UY (1) | UY31039A1 (enExample) |
| WO (1) | WO2008128647A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE281849T1 (de) | 2001-02-28 | 2004-11-15 | Uroteq Inc | Verfahren zur herstellung antimikrobieller polymeroberflächen |
| WO2009082526A2 (en) * | 2007-10-05 | 2009-07-02 | Pharmacopeia, Inc. | Ortho pyrrolidine, benzyl-substituted heterocycle ccr1 antagonists for autoimmune diseases & inflammation |
| AR069494A1 (es) | 2007-11-29 | 2010-01-27 | Actelion Pharmaceuticals Ltd | Derivados de acidos fosfonicos |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| RU2401831C2 (ru) * | 2008-12-15 | 2010-10-20 | Алла Хем, Ллс | Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения |
| AU2010233378A1 (en) * | 2009-04-08 | 2011-11-24 | Actelion Pharmaceuticals Ltd. | 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines as ADP receptor antagonists |
| BRPI1015145A2 (pt) | 2009-04-22 | 2018-01-30 | Actelion Pharmaceuticals Ltd | derivados de tiazol e seu uso como receptores antagonistas de p2y12 |
| JP5597202B2 (ja) | 2009-08-28 | 2014-10-01 | 第一三共株式会社 | 3−(ビアリールオキシ)プロピオン酸誘導体 |
| AR079451A1 (es) * | 2009-12-18 | 2012-01-25 | Nycomed Gmbh | Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina |
| ES2609578T3 (es) | 2011-03-04 | 2017-04-21 | Glaxosmithkline Intellectual Property Development Limited | Amino-quinolinas como inhibidores de quinasa |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| WO2013033178A1 (en) | 2011-08-30 | 2013-03-07 | University Of Utah Research Foundation | Methods and compositions for treating nephrogenic diabetes insipidus |
| CN102584852B (zh) * | 2011-12-30 | 2014-08-13 | 厦门大学 | 真菌代谢产物桥南霉素及其制备方法和应用 |
| AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| AR092530A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| EP2725025A1 (fr) * | 2012-10-26 | 2014-04-30 | Sanofi | Dérives de 1H-indole-3-carboxamide et leurs utilisation comme antagonistes du P2Y12 |
| TWI630203B (zh) | 2013-02-21 | 2018-07-21 | 葛蘭素史克智慧財產發展有限公司 | 做為激酶抑制劑的喹唑啉類 |
| CN104109158A (zh) * | 2013-04-16 | 2014-10-22 | 上海医药工业研究院 | 一种纯化利伐沙班的方法 |
| DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
| DE102015217396B4 (de) | 2014-09-11 | 2018-07-26 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | System, insbesondere System zur Eingabesteuerung für eine Arbeitshilfe |
| CN106496249B (zh) * | 2015-09-07 | 2019-12-13 | 江苏恒瑞医药股份有限公司 | 噁唑并吲哚类衍生物、其制备方法及其在医药上的应用 |
| US10730868B2 (en) * | 2016-07-14 | 2020-08-04 | Bristol-Myers Squibb Company | Bicyclic heteroaryl substituted compounds |
| UA124073C2 (uk) | 2016-09-22 | 2021-07-14 | Ідорсія Фармасьютікалз Лтд | Кристалічні форми гідрохлориду складного бутилового ефіру 4-((r)-2-{[6-((s)-3-метоксипіролідин-1-іл)-2-фенілпіримідин-4-карбоніл]-аміно}-3-фосфонопропіоніл)-піперазин-1-карбонової кислоти |
| MY205605A (en) | 2017-03-15 | 2024-10-29 | Idorsia Pharmaceuticals Ltd | Subcutaneous administration of a p2y12 receptor antagonist |
| CN107648607A (zh) * | 2017-09-11 | 2018-02-02 | 南昌大学 | 嘌呤2y12受体拮抗剂在制备糖尿病神经病理损伤疾病药物中的应用 |
| EP4070658A1 (de) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Verwendung von blutgerinnungshemmenden verbindungen als rodentizide |
| WO2023108363A1 (en) * | 2021-12-13 | 2023-06-22 | Beijing Honghui Meditech Co., Ltd | Pyrimidine-annulated triazole derivatives and their use in platelet aggregation inhibition |
| CN115429874A (zh) * | 2022-09-20 | 2022-12-06 | 暨南大学 | 水蛭素靶向并抑制dpp4治疗糖尿病 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| TR200100149T2 (tr) | 1998-07-06 | 2001-10-22 | Bristol-Myers Squibb Company | Dual anjiyotensin endotelin alıcı antagonistleri olarak bifenil-sülfonamitler |
| AU5546000A (en) | 1999-06-14 | 2001-01-02 | Protherics Molecular Design Limited | Compounds |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| US6861424B2 (en) * | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| BRPI0212726B8 (pt) | 2001-09-21 | 2021-05-25 | Bristol Myers Squibb Co | compostos contendo lactamas, e derivados dos mesmos, composição farmacêutica que os compreende e seus usos |
| CN1747732A (zh) * | 2002-12-11 | 2006-03-15 | 舍林股份公司 | 作为血小板腺苷二磷酸受体拮抗剂的2-氨基羰基喹啉化合物 |
| MXPA06000675A (es) | 2003-07-24 | 2006-04-19 | Astellas Pharma Inc | Derivado de quinolona o sal del mismo. |
| US7157445B2 (en) * | 2004-02-26 | 2007-01-02 | Aventis Pharma S.A. | Administration of enoxaparin sodium to patients with severe renal impairment |
| JP2008094720A (ja) | 2005-01-20 | 2008-04-24 | Astellas Pharma Inc | キノロン誘導体のプロドラッグ又はその塩 |
| TW200640877A (en) * | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| EP1931657B1 (en) * | 2005-08-17 | 2013-12-25 | Merck Sharp & Dohme Corp. | Novel high affinity quinoline-based kinase ligands |
-
2008
- 2008-04-09 CA CA002684644A patent/CA2684644A1/en not_active Abandoned
- 2008-04-09 KR KR1020097022288A patent/KR20100015886A/ko not_active Ceased
- 2008-04-09 BR BRPI0810462-0A2A patent/BRPI0810462A2/pt not_active IP Right Cessation
- 2008-04-09 AU AU2008241091A patent/AU2008241091B2/en not_active Ceased
- 2008-04-09 JP JP2010504490A patent/JP5309131B2/ja not_active Expired - Fee Related
- 2008-04-09 WO PCT/EP2008/002790 patent/WO2008128647A1/en not_active Ceased
- 2008-04-09 CN CN200880013208XA patent/CN101663293B/zh not_active Expired - Fee Related
- 2008-04-09 MY MYPI20094191A patent/MY153427A/en unknown
- 2008-04-09 MX MX2009011089A patent/MX2009011089A/es active IP Right Grant
- 2008-04-09 EP EP08735104A patent/EP2148871A1/en not_active Withdrawn
- 2008-04-21 AR ARP080101660A patent/AR066225A1/es not_active Application Discontinuation
- 2008-04-21 UY UY31039A patent/UY31039A1/es not_active Application Discontinuation
- 2008-04-21 PE PE2008000685A patent/PE20090241A1/es not_active Application Discontinuation
- 2008-04-21 TW TW097114392A patent/TW200848042A/zh unknown
- 2008-04-22 CL CL2008001157A patent/CL2008001157A1/es unknown
- 2008-04-23 PA PA20088777901A patent/PA8777901A1/es unknown
-
2009
- 2009-10-05 US US12/573,551 patent/US8669266B2/en not_active Expired - Fee Related
- 2009-10-19 IL IL201620A patent/IL201620A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CL2008001157A1 (es) | 2008-11-03 |
| US20100135999A1 (en) | 2010-06-03 |
| KR20100015886A (ko) | 2010-02-12 |
| AR066225A1 (es) | 2009-08-05 |
| JP5309131B2 (ja) | 2013-10-09 |
| CA2684644A1 (en) | 2008-10-30 |
| JP2010524984A (ja) | 2010-07-22 |
| MY153427A (en) | 2015-02-13 |
| IL201620A0 (en) | 2010-05-31 |
| HK1141803A1 (en) | 2010-11-19 |
| WO2008128647A1 (en) | 2008-10-30 |
| PE20090241A1 (es) | 2009-04-03 |
| AU2008241091A1 (en) | 2008-10-30 |
| BRPI0810462A2 (pt) | 2014-10-14 |
| PA8777901A1 (es) | 2008-11-19 |
| US8669266B2 (en) | 2014-03-11 |
| MX2009011089A (es) | 2009-10-30 |
| IL201620A (en) | 2013-11-28 |
| CN101663293A (zh) | 2010-03-03 |
| EP2148871A1 (en) | 2010-02-03 |
| AU2008241091B2 (en) | 2013-05-09 |
| CN101663293B (zh) | 2013-07-31 |
| UY31039A1 (es) | 2008-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200848042A (en) | Quinoline-carboxamide derivatives as P2Y12 antagonists | |
| CA3235146A1 (en) | Quinoline compounds as inhibitors of kras | |
| TWI834641B (zh) | 血漿激肽釋放素抑制劑及其用途 | |
| KR20240028539A (ko) | 급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법 | |
| ES2712886T3 (es) | Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa | |
| WO2014151936A9 (en) | Octahydropyrrolopyrroles, their preparation and use | |
| TW201011006A (en) | IAP binding compounds | |
| TW200930375A (en) | Benzofuropyrimidinones | |
| EP2968303A1 (en) | Octahydrocyclopentapyrroles, their preparation and use | |
| TW201026686A (en) | Heterobicyclic carboxamides as inhibitors for kinases | |
| TW200538110A (en) | Pyrrole-derivatives as factor Xa inhibitors | |
| CA3249074A1 (en) | BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS | |
| TW201102396A (en) | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase | |
| JP2022543515A (ja) | 血漿カリクレイン阻害剤 | |
| WO2019043372A1 (en) | SUBSTITUTES OF SULFONYLAZACYCLES USED AS MODULATORS OF THE HEDGEHOG SIGNALING PATHWAY (HH) | |
| WO2023233033A1 (en) | Novel par-2 inhibitors | |
| TW202237578A (zh) | 酶抑制劑 | |
| WO2024084217A1 (en) | 3a,4,5,6-tetrahydro-1 h-pyrazolo[3,4-c]pyridin-7(7ah)-one derivatives as factor xiia inhibitors | |
| CA3256954A1 (en) | Inhibitors of Human Respiratory Syncytial Virus and Human Metapneumovirus | |
| HK1141803B (en) | Quinoline-carboxamide derivatives as p2y12 antagonists | |
| JPWO2007136085A1 (ja) | スピロ四環系化合物 |